Cargando…

Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence

SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Granata, Vincenza, Fusco, Roberta, Setola, Sergio Venanzio, Galdiero, Roberta, Maggialetti, Nicola, Silvestro, Lucrezia, De Bellis, Mario, Di Girolamo, Elena, Grazzini, Giulia, Chiti, Giuditta, Brunese, Maria Chiara, Belli, Andrea, Patrone, Renato, Palaia, Raffaele, Avallone, Antonio, Petrillo, Antonella, Izzo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857317/
https://www.ncbi.nlm.nih.gov/pubmed/36672301
http://dx.doi.org/10.3390/cancers15020351
_version_ 1784873840877240320
author Granata, Vincenza
Fusco, Roberta
Setola, Sergio Venanzio
Galdiero, Roberta
Maggialetti, Nicola
Silvestro, Lucrezia
De Bellis, Mario
Di Girolamo, Elena
Grazzini, Giulia
Chiti, Giuditta
Brunese, Maria Chiara
Belli, Andrea
Patrone, Renato
Palaia, Raffaele
Avallone, Antonio
Petrillo, Antonella
Izzo, Francesco
author_facet Granata, Vincenza
Fusco, Roberta
Setola, Sergio Venanzio
Galdiero, Roberta
Maggialetti, Nicola
Silvestro, Lucrezia
De Bellis, Mario
Di Girolamo, Elena
Grazzini, Giulia
Chiti, Giuditta
Brunese, Maria Chiara
Belli, Andrea
Patrone, Renato
Palaia, Raffaele
Avallone, Antonio
Petrillo, Antonella
Izzo, Francesco
author_sort Granata, Vincenza
collection PubMed
description SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. ABSTRACT: Pancreatic cancer (PC) is one of the deadliest cancers, and it is responsible for a number of deaths almost equal to its incidence. The high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. Pancreatic cystic neoplasms (PCNs) are subsets of lesions which deserve special management to avoid overtreatment. The current PC screening programs are based on the annual employment of magnetic resonance imaging with cholangiopancreatography sequences (MR/MRCP) and/or endoscopic ultrasonography (EUS). For patients unfit for MRI, computed tomography (CT) could be proposed, although CT results in lower detection rates, compared to MRI, for small lesions. The actual major limit is the incapacity to detect and characterize the pancreatic intraepithelial neoplasia (PanIN) by EUS and MR/MRCP. The possibility of utilizing artificial intelligence models to evaluate higher-risk patients could favour the diagnosis of these entities, although more data are needed to support the real utility of these applications in the field of screening. For these motives, it would be appropriate to realize screening programs in research settings.
format Online
Article
Text
id pubmed-9857317
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98573172023-01-21 Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence Granata, Vincenza Fusco, Roberta Setola, Sergio Venanzio Galdiero, Roberta Maggialetti, Nicola Silvestro, Lucrezia De Bellis, Mario Di Girolamo, Elena Grazzini, Giulia Chiti, Giuditta Brunese, Maria Chiara Belli, Andrea Patrone, Renato Palaia, Raffaele Avallone, Antonio Petrillo, Antonella Izzo, Francesco Cancers (Basel) Review SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. ABSTRACT: Pancreatic cancer (PC) is one of the deadliest cancers, and it is responsible for a number of deaths almost equal to its incidence. The high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. Pancreatic cystic neoplasms (PCNs) are subsets of lesions which deserve special management to avoid overtreatment. The current PC screening programs are based on the annual employment of magnetic resonance imaging with cholangiopancreatography sequences (MR/MRCP) and/or endoscopic ultrasonography (EUS). For patients unfit for MRI, computed tomography (CT) could be proposed, although CT results in lower detection rates, compared to MRI, for small lesions. The actual major limit is the incapacity to detect and characterize the pancreatic intraepithelial neoplasia (PanIN) by EUS and MR/MRCP. The possibility of utilizing artificial intelligence models to evaluate higher-risk patients could favour the diagnosis of these entities, although more data are needed to support the real utility of these applications in the field of screening. For these motives, it would be appropriate to realize screening programs in research settings. MDPI 2023-01-05 /pmc/articles/PMC9857317/ /pubmed/36672301 http://dx.doi.org/10.3390/cancers15020351 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Granata, Vincenza
Fusco, Roberta
Setola, Sergio Venanzio
Galdiero, Roberta
Maggialetti, Nicola
Silvestro, Lucrezia
De Bellis, Mario
Di Girolamo, Elena
Grazzini, Giulia
Chiti, Giuditta
Brunese, Maria Chiara
Belli, Andrea
Patrone, Renato
Palaia, Raffaele
Avallone, Antonio
Petrillo, Antonella
Izzo, Francesco
Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title_full Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title_fullStr Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title_full_unstemmed Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title_short Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence
title_sort risk assessment and pancreatic cancer: diagnostic management and artificial intelligence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857317/
https://www.ncbi.nlm.nih.gov/pubmed/36672301
http://dx.doi.org/10.3390/cancers15020351
work_keys_str_mv AT granatavincenza riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT fuscoroberta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT setolasergiovenanzio riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT galdieroroberta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT maggialettinicola riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT silvestrolucrezia riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT debellismario riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT digirolamoelena riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT grazzinigiulia riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT chitigiuditta riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT brunesemariachiara riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT belliandrea riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT patronerenato riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT palaiaraffaele riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT avalloneantonio riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT petrilloantonella riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence
AT izzofrancesco riskassessmentandpancreaticcancerdiagnosticmanagementandartificialintelligence